MedTrace Logo

Study in Adult and Pediatric Patients With HSCT-TMA

NCT04970004 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-05-12

No results posted yet for this study

Summary

This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data required to evaluate study outcomes will be abstracted from the medical records of all patients who meet study eligibility criteria.

Conditions

  • Stem Cell Transplant Complications
  • Thrombotic Microangiopathies

Interventions

OTHER

No intervention

No study intervention will be administered as part of this study.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2022-04-01
Completion
2022-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970004 on ClinicalTrials.gov